NY-198 IN THE SURGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement2-Clinical; pp. 1146 - 1153
• Main Authors: IWAI, SHIGETOMI, FUJII, MASASHI, SATO, TAKESHI, MATSUSHITA, KANEAKI, KUNIMATSU, MASAHIKO, HORIKAWA, AKIRA, FURUHATA, HISASHI, NISHIKAWA, TOURU, KATO, KOUMEI, CHISHIMA, YOSHIAKI, SATO, IZUMI, SASAKI, HIROKO, SAKABE, TAKASHI, USHIO, SATOYA
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement2-Clinical_1146

We basically and clinically investigated NY-198, a new quinoline derivative, and obtained the following results. The ranges of MIC values of NY-198 against clinical isolates were 1.56-6.25μg/ml (coagulase-positive staphylococcus), 0.8-3.13 (coagulase-negative staphylococcus), 6.25-12.5 (E. faecalis), ≤0.05-0.4 (E. coli), 0.2-3.13 (K. pneumoniae), 0.1-3.13 (E. cloacae), 1.56-12.5 (P. aeruginosa), and 12.5-100 (B. fragilis). In one patient given 200mg of NY-198, the peak serum level was 1.76μg/ml at 2h after administration. The peak in pancreatic juice was 1.25μg/ml at 4 h after administration. In the clinical study, NY-198 was administered to 16 patients with mainly skin and soft tissue infections. Clinical response was good in 12 cases (75.0%) and poor in 4. No serious side-effects were noted.